Yuhan Corporation announced on May 14 that it is set to receive a $30 million milestone payment related to the commercialization of its non-small cell lung cancer treatment, Lazertinib, in Europe, following its technology transfer to Janssen Biotech.
This milestone payment is part of a series of payments tied to the European commercialization of Lazertinib and Janssen Biotech's Amivantamab combination therapy.
Although Yuhan's performance in the first quarter fell short of market expectations, the entry of Lazertinib into the European market has raised hopes for improved financial results. With this payment, the total cumulative milestone payments Yuhan has received for Lazertinib (known domestically as Lazertinib) has reached $300 million, including the initial contract fee.
The total milestone payments Yuhan is set to receive amount to $950 million, of which approximately one-third has been received to date. Additionally, Yuhan has begun receiving revenue-based royalties from the combination therapy prescriptions starting in 2024, and the European commercialization is expected to lead to an increase in royalties due to expanded global sales.
Lazertinib is expanding its market presence across four continents: Asia, Europe, America, and Oceania. Notably, it was included in the National Comprehensive Cancer Network (NCCN) guidelines last November as the preferred first-line treatment for EGFR mutation-positive non-small cell lung cancer, establishing itself as a global standard treatment option.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.